An analysis of Medicare Part D formulary files from 2010 to 2020 showed that utilization management has soared for specialty brand and generic oral oncology drugs, with prior authorization used most prevalently. Kelly Anderson, PhD, MPP, said that what the study found “was consistent with my expectations and what we hear anecdotally from clinicians and patients.”